These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9525 related articles for article (PubMed ID: 17709989)

  • 1. Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination.
    Savage P; Dyson J; Milrain M; Mathews D; King B; Chan HT; Barber L; Epenetos A; Ogg G; McMichael A; Glennie MJ; French RR
    Tumour Biol; 2007; 28(4):205-11. PubMed ID: 17709989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
    Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
    Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice.
    Savage P; Cowburn P; Clayton A; Man S; Lawson T; Ogg G; Lemoine N; McMichael A; Epenetos A
    Int J Cancer; 2002 Apr; 98(4):561-6. PubMed ID: 11920616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
    Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
    Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
    Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
    Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy.
    Merrick A; Diaz RM; O'Donnell D; Selby P; Vile R; Melcher A
    Cancer Immunol Immunother; 2008 Jun; 57(6):897-906. PubMed ID: 18057935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
    Griffiths E; Ong H; Soloski MJ; Bachmann MF; Ohashi PS; Speiser DE
    Cancer Res; 1998 Oct; 58(20):4682-7. PubMed ID: 9788622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TCR-independent killing of B cell malignancies by anti-third-party CTLs: the critical role of MHC-CD8 engagement.
    Lask A; Goichberg P; Cohen A; Goren-Arbel R; Milstein O; Aviner S; Feine I; Ophir E; Reich-Zeliger S; Hagin D; Klein T; Nagler A; Berrebi A; Reisner Y
    J Immunol; 2011 Aug; 187(4):2006-14. PubMed ID: 21753148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.
    Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW
    J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    Morrison BJ; Steel JC; Morris JC
    BMC Cancer; 2018 Apr; 18(1):469. PubMed ID: 29699516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.
    King BC; Hamblin AD; Savage PM; Douglas LR; Hansen TH; French RR; Johnson PW; Glennie MJ
    Cancer Immunol Immunother; 2013 Jun; 62(6):1093-105. PubMed ID: 23604105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens.
    Bernhardt AL; Zeun J; Marecek M; Reimann H; Kretschmann S; Bausenwein J; van der Meijden ED; Karg MM; Haug T; Meintker L; Lutzny-Geier G; Mackensen A; Kremer AN
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
    Palmowski M; Salio M; Dunbar RP; Cerundolo V
    Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of naïve T cells recognizing the minor histocompatibility antigen HY with toxin-coupled peptide-MHC class I tetramers inhibits cognate CTL responses and alters immunodominance.
    Hess SM; Young EF; Miller KR; Vincent BG; Buntzman AS; Collins EJ; Frelinger JA; Hess PR
    Transpl Immunol; 2013 Dec; 29(1-4):138-45. PubMed ID: 24161680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
    Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
    Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
    Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice.
    Kievits F; Wijffels J; Lokhorst W; Ivanyi P
    Proc Natl Acad Sci U S A; 1989 Jan; 86(2):617-20. PubMed ID: 2783490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 477.